Annual EBIT
-$235.88 M
-$273.68 M-724.00%
31 December 2023
Summary:
Cartesian Therapeutics annual earnings before interest & taxes is currently -$235.88 million, with the most recent change of -$273.68 million (-724.00%) on 31 December 2023. During the last 3 years, it has fallen by -$168.56 million (-250.38%). RNAC annual EBIT is now -724.00% below its all-time high of $39.09 million.RNAC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$24.18 M
-$38.02 M-274.78%
01 September 2024
Summary:
Cartesian Therapeutics quarterly earnings before interest & taxes is currently -$24.18 million, with the most recent change of -$38.02 million (-274.78%) on 01 September 2024. Over the past year, it has dropped by -$16.45 million (-212.89%). RNAC quarterly EBIT is now -182.02% below its all-time high of $29.48 million, reached on 01 March 2022.RNAC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$263.83 M
-$16.45 M-6.65%
01 September 2024
Summary:
Cartesian Therapeutics TTM earnings before interest & taxes is currently -$263.83 million, with the most recent change of -$16.45 million (-6.65%) on 01 September 2024. Over the past year, it has dropped by -$231.02 million (-704.19%). RNAC TTM EBIT is now -622.08% below its all-time high of $50.53 million, reached on 01 June 2022.RNAC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAC EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -724.0% | -212.9% | -704.2% |
| 3 y3 years | -250.4% | -1684.7% | -660.4% |
| 5 y5 years | -269.5% | -108.4% | -392.8% |
RNAC EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -724.0% | at low | -182.0% | +87.7% | -622.1% | +3.0% |
| 5 y | 5 years | -724.0% | at low | -182.0% | +87.7% | -622.1% | +3.0% |
| alltime | all time | -724.0% | at low | -182.0% | +87.7% | -622.1% | +3.0% |
Cartesian Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$24.18 M(-274.8%) | -$263.83 M(+6.7%) |
| June 2024 | - | $13.84 M(-124.3%) | -$247.38 M(-9.0%) |
| Mar 2024 | - | -$56.82 M(-71.1%) | -$271.85 M(+15.2%) |
| Dec 2023 | -$235.88 M(-724.0%) | -$196.66 M(+2444.4%) | -$235.88 M(+619.0%) |
| Sept 2023 | - | -$7.73 M(-27.3%) | -$32.81 M(+1.0%) |
| June 2023 | - | -$10.63 M(-49.0%) | -$32.49 M(+159.1%) |
| Mar 2023 | - | -$20.86 M(-425.2%) | -$12.54 M(-133.2%) |
| Dec 2022 | $37.80 M(-649.7%) | - | - |
| Dec 2022 | - | $6.41 M(-186.5%) | $37.80 M(-15.0%) |
| Sept 2022 | - | -$7.41 M(-179.6%) | $44.48 M(-12.0%) |
| June 2022 | - | $9.32 M(-68.4%) | $50.53 M(+8.7%) |
| Mar 2022 | - | $29.48 M(+125.3%) | $46.49 M(-776.1%) |
| Dec 2021 | -$6.88 M(-89.8%) | $13.09 M(-1065.9%) | -$6.88 M(-80.2%) |
| Sept 2021 | - | -$1.35 M(-125.7%) | -$34.70 M(-18.8%) |
| June 2021 | - | $5.28 M(-122.1%) | -$42.71 M(-40.6%) |
| Mar 2021 | - | -$23.89 M(+62.1%) | -$71.86 M(+6.7%) |
| Dec 2020 | -$67.32 M(+25.1%) | -$14.73 M(+57.3%) | -$67.32 M(+0.3%) |
| Sept 2020 | - | -$9.36 M(-60.8%) | -$67.14 M(-3.2%) |
| June 2020 | - | -$23.88 M(+23.4%) | -$69.38 M(+12.8%) |
| Mar 2020 | - | -$19.35 M(+32.9%) | -$61.50 M(+14.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$53.83 M(-15.7%) | -$14.55 M(+25.4%) | -$53.83 M(+0.6%) |
| Sept 2019 | - | -$11.61 M(-27.4%) | -$53.53 M(-7.0%) |
| June 2019 | - | -$15.99 M(+37.0%) | -$57.55 M(-4.1%) |
| Mar 2019 | - | -$11.68 M(-18.1%) | -$59.98 M(-6.0%) |
| Dec 2018 | -$63.84 M(-0.4%) | -$14.26 M(-8.7%) | -$63.84 M(-7.2%) |
| Sept 2018 | - | -$15.62 M(-15.3%) | -$68.77 M(+1.8%) |
| June 2018 | - | -$18.43 M(+18.6%) | -$67.56 M(+4.2%) |
| Mar 2018 | - | -$15.54 M(-19.0%) | -$64.82 M(+1.1%) |
| Dec 2017 | -$64.11 M(+83.4%) | -$19.18 M(+33.2%) | -$64.11 M(+9.2%) |
| Sept 2017 | - | -$14.41 M(-8.2%) | -$58.69 M(+13.5%) |
| June 2017 | - | -$15.69 M(+5.8%) | -$51.70 M(+21.3%) |
| Mar 2017 | - | -$14.83 M(+7.8%) | -$42.63 M(+21.9%) |
| Dec 2016 | -$34.96 M(+44.3%) | -$13.76 M(+85.5%) | -$34.96 M(+25.1%) |
| Sept 2016 | - | -$7.42 M(+12.2%) | -$27.94 M(+7.8%) |
| June 2016 | - | -$6.61 M(-7.7%) | -$25.91 M(+0.3%) |
| Mar 2016 | - | -$7.17 M(+6.3%) | -$25.84 M(+6.7%) |
| Dec 2015 | -$24.23 M(+96.5%) | -$6.74 M(+25.1%) | -$24.23 M(+38.6%) |
| Sept 2015 | - | -$5.39 M(-17.5%) | -$17.48 M(+44.6%) |
| June 2015 | - | -$6.54 M(+17.7%) | -$12.09 M(+117.7%) |
| Mar 2015 | - | -$5.55 M | -$5.55 M |
| Dec 2014 | -$12.33 M | - | - |
FAQ
- What is Cartesian Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Cartesian Therapeutics?
- What is Cartesian Therapeutics annual EBIT year-on-year change?
- What is Cartesian Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Cartesian Therapeutics?
- What is Cartesian Therapeutics quarterly EBIT year-on-year change?
- What is Cartesian Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Cartesian Therapeutics?
- What is Cartesian Therapeutics TTM EBIT year-on-year change?
What is Cartesian Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RNAC is -$235.88 M
What is the all time high annual EBIT for Cartesian Therapeutics?
Cartesian Therapeutics all-time high annual earnings before interest & taxes is $39.09 M
What is Cartesian Therapeutics annual EBIT year-on-year change?
Over the past year, RNAC annual earnings before interest & taxes has changed by -$273.68 M (-724.00%)
What is Cartesian Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RNAC is -$24.18 M
What is the all time high quarterly EBIT for Cartesian Therapeutics?
Cartesian Therapeutics all-time high quarterly earnings before interest & taxes is $29.48 M
What is Cartesian Therapeutics quarterly EBIT year-on-year change?
Over the past year, RNAC quarterly earnings before interest & taxes has changed by -$16.45 M (-212.89%)
What is Cartesian Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RNAC is -$263.83 M
What is the all time high TTM EBIT for Cartesian Therapeutics?
Cartesian Therapeutics all-time high TTM earnings before interest & taxes is $50.53 M
What is Cartesian Therapeutics TTM EBIT year-on-year change?
Over the past year, RNAC TTM earnings before interest & taxes has changed by -$231.02 M (-704.19%)